newsfilter
← Latest News
GlobeNewswire·

Longeveron Rights Offering Subscription Period Begins

MIAMI, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN, NASDAQ:LGVNR) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic